Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell®)

Table 7 Primary and secondary efficacy criteria: complete or partial abstinence during the 28 days preceding the 6-week visit (adopted from [17])

Group\Statistical results	Nicotinell^® lozenge 1 mg	Placebo
	(n = 211)	(n = 222)
Complete abstinence (%)	48 (23%)	32 (14%)
OR [95% CI]	1.72 [1.05–2.80]
Statistical significance	p = 0.03
Complete or partial abstinence (%)	68 (32%)	39 (18%)
OR [95% CI]	2.18 [1.40–3.41]
Statistical significance	p = 0.001

Complete abstinence = subjects declaring not to smoke + exhaled-breath CO <10 ppm. Partial abstinence = subjects smoking ≤ 1 cigarette/day and ≤ 7 cigarettes/week + exhaled-breath CO <10 ppm.